RECRUITINGINTERVENTIONAL
Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
About This Trial
This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.
Who May Be Eligible (Plain English)
Who May Qualify:
- Breast cancer stage I-III
Who Should NOT Join This Trial:
- pregnant, lactation, breast recurrence, mental disease, autoimmune conditions (where your immune system attacks your own body) over hte past 5 years, people who take plant or fungal polysaccharide health supplements
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Breast cancer stage I-III
Exclusion Criteria:
* pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements
Treatments Being Tested
DIETARY_SUPPLEMENT
Biobran supplementation
3 g Biobran per day for 24 weeks
Locations (2)
China Medical University Hospital
Taichung, Taiwan
China Medical University
Taichung, Taiwan